Posted on October 15, 2019 by TMS Clinics Australia


The Medical Services Advisory Committee (MSAC) responsible for advising on Medicare reimbursements has recommended public funding of TMS therapy for the treatment of depression in Australia. Medicare funding is anticipated to come into effect sometime in 2021, with many specifics still needing to be agreed upon.


Professor Paul Fitzgerald, Medical Director of TMS Clinics Australia, is enthusiastic about the development - 

“TMS being recommended a Medicare item number is a great endorsement of the treatment. There is still work to go until implementation, but this will open this treatment to many more patients.”


What does this mean for patients wanting TMS treatment?

This development means that more Australians will have access to Transcranial Magnetic Stimulation at little or no out-of-pocket cost through Medicare, with or without private health insurance.


“If you have tried 2 antidepressants and don’t get better, TMS is statistically more likely to help than another medication.”, according to Dr Ted Cassidy, Chief Medical Officer of TMS Clinics Australia, “but many patients unnecessarily have to go into hospital to receive TMS treatment. This is all about to change”. 


What happens between now and the anticipated Medicare funding?

Until TMS is funded by Medicare, TMS Clinics Australia will continue to work on behalf of patients to secure funding through Department of Veterans' Affairs, Workers' Compensation, and select health funds. Private patients can benefit from payment plans or early access to their superannuation.


For more information, contact our Patient Care Team on 1300 867 888.